title: Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity in vivo.
abstract: Detachment from the extracellular matrix causes apoptosis of normal epithelial cells--a phenomenon called anoikis. K-ras oncogene, an established anoikis inhibitor, often occurs in colorectal carcinoma (CRC). In addition to blocking anoikis-inducing mechanisms, oncogenic K-ras can cause anoikis-unrelated changes in CRC cells, such as induction of events promoting their deregulated mitogenesis, ability to trigger angiogenesis, and so on. Thus, whether ras-induced anoikis resistance of CRC cells is essential for their ability to form tumors in vivo or represents a mere epiphenomenon is unclear. We found that when poorly tumorigenic, oncogenic, K-ras-negative, anoikis-susceptible human CRC cells were cultured under anoikis-inducing conditions in vitro, they spontaneously gave rise to an anoikis-resistant cell population harboring de novo oncogenic K-ras mutations and manifesting dramatically increased tumorigenicity. We further observed that a variant of the same oncogenic K-ras-negative anoikis-susceptible cells selected for increased tumorigenicity acquired de novo oncogenic K-ras mutations and manifested increased anoikis resistance. Unlike the case with anoikis, oncogenic K-ras did not rescue CRC cells from death caused by hypoxia or anticancer agents. Taken collectively, our results support the notion that ras-induced anoikis resistance of CRC cells is essential for their ability to form tumors in vivo and thus represents a potential therapeutic target.
authors: Department of Pediatrics, Atlantic Research Center, Dalhousie University, Halifax, Nova Scotia, Canada.
authors: Mathieu
authors: M
authors: Derouet
authors: Xue
authors: X
authors: Wu
authors: Linda
authors: L
authors: May
authors: Byong
authors: B
authors: Hoon Yoo
authors: Takehiko
authors: T
authors: Sasazuki
authors: Senji
authors: S
authors: Shirasawa
authors: Janusz
authors: J
authors: Rak
authors: Kirill V
authors: KV
authors: Rosen
mesh_terms: D023102:Anoikis / Q000235:genetics*; D002277:Carcinoma / Q000235:genetics*; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D015179:Colorectal Neoplasms / Q000235:genetics*; D006801:Humans; D009154:Mutation; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics / Q000502:physiology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: D016159:Tumor Suppressor Protein p53; D016283:Proto-Oncogene Proteins p21(ras)
references: Ann Oncol. 2002 Dec;13(12):1841-51
references: 12453851
references: J Biol Chem. 2002 Nov 29;277(48):46123-30
references: 12356751
references: EMBO J. 2003 Aug 15;22(16):4091-102
references: 12912908
references: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3615-9
references: 14506148
references: Oncogene. 2003 Dec 8;22(56):9063-74
references: 14663485
references: Nat Rev Drug Discov. 2004 May;3(5):391-400
references: 15136787
references: Nature. 2004 Aug 26;430(7003):1034-9
references: 15329723
references: Nature. 1987 May 28-Jun 3;327(6120):293-7
references: 3587348
references: Cell. 1990 Jun 1;61(5):759-67
references: 2188735
references: Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9
references: 1699228
references: Int J Cancer. 1992 Feb 20;50(4):562-6
references: 1371500
references: Science. 1993 Apr 2;260(5104):85-8
references: 8465203
references: J Cell Biol. 1994 Feb;124(4):619-26
references: 8106557
references: Oncogene. 1994 Dec;9(12):3627-33
references: 7970723
references: Oncogene. 1995 Apr 6;10(7):1413-6
references: 7731692
references: Cancer Res. 1996 May 1;56(9):2161-6
references: 8616866
references: Science. 1998 Nov 20;282(5393):1497-501
references: 9822382
references: Curr Biol. 1998 Dec 3;8(24):1331-4
references: 9843689
references: J Clin Invest. 1999 Aug;104(3):263-9
references: 10430607
references: Blood. 2005 Feb 15;105(4):1734-41
references: 15494427
references: Cancer Res. 2005 Mar 15;65(6):2378-86
references: 15781653
references: Biochem Biophys Res Commun. 2005 Jun 10;331(3):718-25
references: 15865928
references: J Natl Cancer Inst. 2005 Jul 6;97(13):981-9
references: 15998951
references: Cancer Res. 2005 Sep 15;65(18):8134-41
references: 16166287
references: J Biol Chem. 2005 Nov 11;280(45):37383-92
references: 16115895
references: J Biol Chem. 2006 May 26;281(21):14738-47
references: 16461771
references: Anticancer Res. 2006 Jan-Feb;26(1B):511-22
references: 16739312
references: J Cell Biol. 2000 Apr 17;149(2):447-56
references: 10769035
references: J Biol Chem. 2000 May 26;275(21):15728-32
references: 10748105
references: Oncologist. 2001;6(1):65
references: 11161229
references: J Biol Chem. 2001 Oct 5;276(40):37273-9
references: 11487584
references: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8265-70
references: 12060769
references: Nat Rev Cancer. 2002 Aug;2(8):594-604
references: 12154352
references: Lancet. 2003 Jul 19;362(9379):230-2
references: 12885487